The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
A cold start to the day but lots of sunshine. Likely to remain largely dry into the afternoon with strong winds continuing.
A cold night with a yellow warning in force for snow and ice. Winds will remain strong but a largely dry and bright day tomorrow.
In the first of our specials looking at the Welsh education system, we visited a new primary school in Llanelli.